Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy.
Multiple sclerosis journal - experimental, translational and clinical（2019）
Abstract
Teriflunomide therapy initiated without natalizumab washout resulted in a low rate of return of disease activity. Clinicians may consider this a worthwhile strategy when transitioning clinically stable patients off natalizumab to another therapy.ClinicalTrials.gov Identifier: NCT01970410.
MoreTranslated text
Key words
Relapsing multiple sclerosis,anti-JC virus antibodies,disease recurrence,natalizumab,switch strategy,teriflunomide
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined